Clinical development of anti-tuberculosis drugs.

In the clinical development of new anti-tuberculosis drugs, the most important step is efficient Phase II studies to show whether the drug is likely to be able to shorten treatment and with what other drugs it has the greatest sterilizing activity. The use of non-linear mixed effects modelling applied to serial sputum cfu counts appears to be the most effective technique, but we know little about the optimal design of such novel studies. A paper in the current journal reports on the relative efficiencies of various timing patterns in sampling sputum.

[1]  L. Aarons,et al.  Optimal sampling strategies for early pharmacodynamic measures in tuberculosis. , 2006, The Journal of antimicrobial chemotherapy.

[2]  L. Aarons,et al.  Use of Nonlinear Mixed-Effects Analysis for Improved Precision of Early Pharmacodynamic Measures in Tuberculosis Treatment , 2006, Antimicrobial Agents and Chemotherapy.

[3]  D. Mitchison,et al.  The early bactericidal activities of rifampin and rifapentine in pulmonary tuberculosis. , 2005, American journal of respiratory and critical care medicine.

[4]  R. Chaisson,et al.  Moxifloxacin-containing regimen greatly reduces time to culture conversion in murine tuberculosis. , 2004, American journal of respiratory and critical care medicine.

[5]  D. Mitchison,et al.  Serial counts of Mycobacterium tuberculosis in sputum as surrogate markers of the sterilising activity of rifampicin and pyrazinamide in treating pulmonary tuberculosis , 2001, BMC pulmonary medicine.

[6]  Tuberculosis. Scientific blueprint for tuberculosis drug development. , 2001, Tuberculosis.

[7]  L B Sheiner,et al.  Pharmacokinetic/pharmacodynamic modeling in drug development. , 2000, Annual review of pharmacology and toxicology.

[8]  M. Vandenplas,et al.  The early bactericidal activity of isoniazid related to its dose size in pulmonary tuberculosis. , 1997, American journal of respiratory and critical care medicine.

[9]  D. Mitchison.  Modern methods for assessing the drugs used in the chemotherapy of mycobacterial disease. , 1996, Society for Applied Bacteriology symposium series.

[10]  D. Mitchison,et al.  The early bactericidal activity of rifabutin in patients with pulmonary tuberculosis measured by sputum viable counts: a new method of drug assessment. , 1993, The Journal of antimicrobial chemotherapy.